Phase IV

August 19, 2019

ESC preview – Medicines Company hopes for a starring role

Novartis has been reduced to a Paragon data dredge, but results with The Medicines Company’s inclisiran, Astrazeneca’s Brilinta and Cellaegis’ AutoRIC device should pique interest.

ESC preview – Medicines Company hopes for a starring role

Boston Scientific’s plan to keep the rhythm going

Ablation groups scramble to cope with Cabana

GeneSight trial miss leaves Myriad depressed

Vifor takes iron therapy expansion to heart

Smith & Nephew innovates in wound care, but no trade sale in sight

TCT 2016: Early clinical data back Medtronic’s inside-out stent

Interview – Xhale helps pharma breathe easy on compliance

Glaxo shoots itself in the foot... again

Cardiovascular radiance for Jardiance

Veracyte sets sights on payment for lung cancer test

Latest Reports

Vantage Pharma, Biotech & Medtech 2019 in Review

Vantage 2020 Preview

Editor's Picks

The cost to Astrazeneca of building Brilinta

Rare diseases top another strong year for novel drug approvals

Surprise! There’s a tumour in which Keytruda doesn’t work

A quiet six months for device approvals

Sanofi's geriatric pipeline fails to freshen up